All In Biotech

Drug Trial Radar · NCT07837648

A Study to Test How Much BI 3034701 Gets Into the Blood in Healthy People When Given in Two Different Ways

Relative Bioavailability of Two Different BI 3034701 Treatments Following Subcutaneous Administration in Healthy Male and Female Participants (an Open-label, Randomised, Single-dose, Two-period, Two-sequence, Crossover Trial)

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Oct 5, 2026

Primary completion

Dec 15, 2026

Study completion Dec 24, 2026

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Sep 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of the trial is to investigate relative bioavailability of BI 3034701 treatment T vs. BI 3034701 treatment R.

Conditions

  • Healthy

Interventions

  • BI3034701 formulation IIDrug

    BI3034701 formulation II (reference treatment)

  • BI3034701 formulation C1Drug

    BI3034701 formulation C1 (test treatment)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)Time frame: Up to 19 days.
  2. Maximum measured concentration of the analyte in plasma (Cmax)Time frame: Up to 19 days.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quotient Sciences

    Nottingham, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.